ClinicalTrials.gg
Not yet recruitingNCT07538154Updated Apr 20, 2026

A Clinica Study of SCTC21C in Participants With Systemic Lupus Erythematosus

A Phase 1/2 interventional study of SCTC21C in Systemic Lupus Erythematosus (SLE), sponsored by Sinocelltech Ltd.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Sinocelltech Ltd. (part of Sinocelltech Group Limited) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
159
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SCTC21C in participants with systemic lupus erythematosus

Read the detailed description

This study contains phase Ib and phase II studies. In phase Ib study, participants will be assigned to receive sequentially higher doses of SCTC21C to determine the recomended dose of SCTC21C for the randomized dose optimation-stage. In phase 2 study, 2 dose levels will be uased. A total of 120 participants will be randomized in a 1:1:1 ration to dose 1, dose 2 or placebo groups to better understand the exposure/efficacy/toxicity relationship.

02

Conditions studied

  • Systemic Lupus Erythematosus (SLE)

Keywords

  • SLE
03

In context

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

This study's planned enrollment of 159 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.

Browse Lupus Erythematosus, Systemic studies →

Lead sponsor

Sinocelltech Ltd. is the lead sponsor of 82 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18-75 years;
  2. Diagnosed with SLE for ≥12 weeks prior to screening, met the 2019 ACR/EULAR diagnostic criteria for SLE screening period;
  3. SELENA-SLEDAI ≥8 at screening;
  4. Positive immunological markers within 12 months prior to baseline;
  5. Currently receiving ≥1 stable doses of standard treatment: oral , antimalarials, or conventional drugs;
  6. All male participants or females of must agree to use reliable with their partner from signing the ICF through 5 months after the last dose of the study drug
  7. Understanding of the study procedures and voluntary signing of the form

Exclusion criteria

Exclusion Criteria:

  1. Severe active or unstable lupus-related neuropsychiatric disorders;
  2. Combined with active infections, malignant tumors, or other diseases;
  3. Catastrophic antiphospholipid syndrome;
  4. severe lupus nephritis;
  5. Study participants who received a live or attenuated vaccine within 28 days prior to baseline or during the screening period;
  6. Received any treatment within 30 days prior to baseline or within 5 half-lives of the investigational drug (whichever is longer);
  7. Patients at high risk of severe clinical bleeding, or those requiring plasma transfusion, intravenous immunoglobulin, or acute blood products;;
  8. Patients who experienced any of the following cardiovascular or cerebrovascular events within 24 weeks prior to baseline: myocardial infarction, unstable angina, ventricular arrhythmia, (NYHA) Class II or higher heart failure, stroke, etc.;
  9. In accordance with the protocol requirements, participants with abnormal laboratory test results;
  10. Participants with positive results of viral serology, including Treponema pallidum, , , and ;
  11. participants with a history of tuberculosis or latent tuberculosis infection;
  12. Diagnosed with type 1 or type 2 diabetes with poor control;
  13. Uncontrolled hypertension;
  14. Intolerance to the study drug or , including a history of severe allergic reactions to monoclonal antibodies or any component of SCTC21C injection;
  15. Required hospitalization for major surgery within 4 weeks prior to screening or within 12 weeks post-study drug administration;
  16. History of solid organ or hematopoietic stem cell/bone marrow transplant, or expected to undergo transplant surgery during the study;
  17. Pregnant or breastfeeding;
  18. Any other condition that the investigator deems unsuitable for participation in the study
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
159 participants (estimated)

Study arms

  • Experimental
    experimental: SCTC21C

    SCTC21C will be administered to participants for about 24 weeks

    Biological: SCTC21C

Interventions

  • BiologicalSCTC21C

    SCTC21C will be subcutaneously administered at a dose as specified in the respective dose-escalation cohorts. Then, the RP2D and other appropriate doses of SCTC21C will be applied for the dose-expansion cohorts

06

What researchers measure

Primary outcomes

  1. Phase 1: safety and tolerability of SCTC21C

    To evaluate the incidence rates of treatment emergent adverse event (TEAE), treatment-related TEAE (TRAE), serious adverse event (SAE) and dose-limiting toxicity (DLT)

    Time frame: From first dose to Week 48

  2. Phase II: efficacy of SCTC21C

    Percentage of participants who achiened an mSRI-4 response at W24

    Time frame: Up to Week 24

Secondary outcomes

  1. dose escalation part#SRI4/5/6/7/8

    percentage of participants who achieved SRI4/5/6/7/8 response at specified time

    Time frame: up to Week 48

  2. Dose- escalation # mSRI4/5/6/7/8

    percentage of participants who achieved mSRI4/5/6/7/8 response at specified time

    Time frame: up to Week 48

  3. Dose-escalation part # BILAG

    The BILAG improvement rate among participants with baseline BILAG score of A or B at specified time

    Time frame: up to Week 48

  4. Dose-escalation part # SLE flare

    Time to first SLE flare

    Time frame: Up to Week 48

  5. Dose-escalation part # immunogenicity

    Serum anti-SCTC21C antibody and anti-SCTC21C neutralization antibody levels

    Time frame: up to Week 48

  6. Dose-escalation part # SCTC21C

    Serum SCTC21C levels at specified time

    Time frame: up to Week 48

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Apr 2027, 12 months later.

Of 37 phase 1/2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 60. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2026
First posted
Apr 20, 2026
StartEst.
Apr 2026
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2028
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07538154
Lead sponsor
Sinocelltech Ltd.
Responsible party
Sponsor
First posted
Apr 20, 2026
Start date
Apr 2026 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Apr 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD38 Monoclonal Antibody SCTC21C

Start the discussion